Total Payments
$497,258
2024 Payments
$164,617
Companies
19
Transactions
569
Medicare Patients
32,663
Medicare Billing
$26.1M
Payment Breakdown by Category
Other$381,767 (76.8%)
Travel$64,027 (12.9%)
Consulting$34,617 (7.0%)
Food & Beverage$16,789 (3.4%)
Education$38.00 (0.0%)
Gifts$19.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $378,817 | 68 | 76.2% |
| Travel and Lodging | $64,027 | 187 | 12.9% |
| Consulting Fee | $34,617 | 13 | 7.0% |
| Food and Beverage | $16,789 | 296 | 3.4% |
| Honoraria | $2,950 | 3 | 0.6% |
| Education | $38.00 | 1 | 0.0% |
| Gift | $19.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech USA, Inc. | $143,329 | 161 | $0 (2024) |
| Astellas Pharma US Inc | $102,937 | 127 | $0 (2024) |
| Biogen, Inc. | $94,466 | 87 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $66,775 | 50 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $39,684 | 30 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $23,225 | 30 | $0 (2024) |
| Allergan, Inc. | $7,869 | 19 | $0 (2021) |
| Alimera Sciences, Inc. | $6,175 | 35 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $5,717 | 5 | $0 (2024) |
| Genentech, Inc. | $4,526 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $164,617 | 178 | Astellas Pharma US Inc ($59,079) |
| 2023 | $176,963 | 189 | Biogen, Inc. ($70,108) |
| 2022 | $68,680 | 65 | Genentech USA, Inc. ($44,103) |
| 2021 | $9,976 | 28 | Allergan, Inc. ($7,621) |
| 2020 | $1,261 | 16 | Alimera Sciences, Inc. ($976.64) |
| 2019 | $66,831 | 54 | Novartis Pharmaceuticals Corporation ($66,428) |
| 2018 | $6,364 | 25 | Genentech USA, Inc. ($4,860) |
| 2017 | $2,566 | 14 | Alimera Sciences, Inc. ($2,187) |
All Payment Transactions
569 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $508.95 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | In-kind items and services | $304.92 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $24.12 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $19.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $3,315.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,210.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/13/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $26.63 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | Cash or cash equivalent | $27.58 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/12/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | Cash or cash equivalent | $11.53 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/11/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Travel and Lodging | Cash or cash equivalent | $117.07 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/11/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Food and Beverage | Cash or cash equivalent | $62.78 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 12/10/2024 | EyePoint Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $23.68 | General |
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/06/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,720.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 12/03/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $88.38 | General |
| Category: Ophthalmology | ||||||
| 12/03/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $24.87 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $39.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/23/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $120.14 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/21/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,670.00 | General |
| Category: Ophthalmology | ||||||
| 11/21/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: Ophthalmology | ||||||
| 11/19/2024 | Biogen, Inc. | BYOOVIZ (Biological) | Food and Beverage | In-kind items and services | $91.93 | General |
| Category: Ophthalmology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 6,560 | 55,009 | $20.5M | $6.0M |
| 2022 | 27 | 7,469 | 32,951 | $23.9M | $6.8M |
| 2021 | 29 | 9,661 | 36,014 | $29.8M | $7.8M |
| 2020 | 26 | 8,973 | 29,837 | $16.3M | $5.5M |
Total Patients
32,663
Total Services
153,811
Medicare Billing
$26.1M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 489 | 4,710 | $8.4M | $3.2M | 38.4% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 117 | 33,060 | $2.6M | $958,493 | 36.2% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 124 | 3,105 | $1.6M | $527,702 | 34.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 871 | 3,353 | $3.9M | $335,983 | 8.6% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 101 | 1,242 | $659,940 | $228,407 | 34.6% |
| 92134 | Imaging of retina | Office | 2023 | 1,697 | 4,532 | $679,698 | $140,999 | 20.7% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 63 | 577 | $386,590 | $124,679 | 32.3% |
| J3490 | Unclassified drugs | Office | 2023 | 30 | 48 | $392,500 | $89,731 | 22.9% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 594 | 1,189 | $389,130 | $81,721 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 776 | 951 | $294,810 | $59,697 | 20.2% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 498 | 536 | $262,160 | $57,655 | 22.0% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 14 | 315 | $97,650 | $37,914 | 38.8% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 326 | 384 | $172,800 | $33,279 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 181 | 181 | $102,570 | $22,089 | 21.5% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 21 | 21 | $92,790 | $17,934 | 19.3% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Office | 2023 | 41 | 49 | $71,180 | $13,075 | 18.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 137 | 137 | $52,060 | $11,711 | 22.5% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 12 | 12 | $57,600 | $11,385 | 19.8% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 63 | 156 | $85,800 | $11,372 | 13.3% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 14 | 15 | $56,870 | $11,315 | 19.9% |
| 92250 | Photography of the retina | Office | 2023 | 211 | 236 | $32,570 | $6,479 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 32 | 33 | $14,520 | $3,006 | 20.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 28 | 28 | $14,620 | $2,392 | 16.4% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 47 | 63 | $11,520 | $2,292 | 19.9% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 11 | 11 | $11,750 | $2,274 | 19.4% |
About Dr. Carlos Medina Mendez, M.D
Dr. Carlos Medina Mendez, M.D is a Ophthalmology healthcare provider based in Sacramento, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/18/2010. The National Provider Identifier (NPI) number assigned to this provider is 1811218316.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carlos Medina Mendez, M.D has received a total of $497,258 in payments from pharmaceutical and medical device companies, with $164,617 received in 2024. These payments were reported across 569 transactions from 19 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($378,817).
As a Medicare-enrolled provider, Medina Mendez has provided services to 32,663 Medicare beneficiaries, totaling 153,811 services with total Medicare billing of $26.1M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Ophthalmology, Ophthalmology
- Location Sacramento, CA
- Active Since 06/18/2010
- Last Updated 04/03/2017
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1811218316
Products in Payments
- Izervay (Drug) $79,351
- Vabysmo (Drug) $77,431
- VABYSMO (Drug) $43,284
- Syfovre (Drug) $35,762
- EYLEA HD (Biological) $28,766
- BEOVU (Drug) $19,220
- Susvimo (Drug) $8,868
- OZURDEX (Drug) $7,759
- Lucentis (Biological) $7,515
- ILUVIEN (Drug) $2,254
- Iluvien (Biological) $2,147
- EYP-1901 (Drug) $1,602
- SUSVIMO (Drug) $822.81
- Iluvien (Drug) $373.23
- Constellation (Device) $271.65
- YUTIQ (Drug) $223.79
- ACTHAR (Biological) $143.92
- BYOOVIZ (Biological) $133.19
- Cimerli (Biological) $125.00
- EYLEA (Biological) $122.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Sacramento
Richard Lewis, Md, MD
Ophthalmology — Payments: $455,999
Ophthalmology $455,999
Dr. Lawrence Morse, M.d, M.D
Ophthalmology — Payments: $196,712
Ophthalmology $196,712
Dr. Samuel Lee, M.d, M.D
Ophthalmology — Payments: $186,131
Ophthalmology $186,131
Margaret Chang, M.d, M.D
Ophthalmology — Payments: $178,138
Ophthalmology $178,138
Glenn Yiu, Md, Phd, MD, PHD
Ophthalmology — Payments: $153,812
Ophthalmology $153,812
Dr. Jeffrey Caspar, M.d, M.D
Ophthalmology — Payments: $78,720
Ophthalmology $78,720